Boston, MA -- (SBWIRE) -- 01/06/2014 -- Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management

Summary

GBI Research has released the pharma report "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management". The Parkinson's Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012-2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan. Although a few market entrants are anticipated to enter the market over the forecast period, they are not expected to offset the impact of generic erosion. Despite their superior profiles over existing treatments, these new products are not expected to command a premium price as they will be competing against generic products. The current PD pipeline reflects a shift of focus to long-term PD management, marked by the development of key pipeline candidates targeting levodopa-associated motor complications. These products will have the potential to change the future treatment algorithm as side effects of dopaminergic therapies become more manageable.

View Full Report Details and Table of Contents

Scope

- A brief introduction to PD, including pathogenesis, disease staging, diagnosis and treatment algorithms
- In-depth analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
- Comprehensive review of the pipeline for PD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of phase distribution, molecule type and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario market forecast data to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
- Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
- MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts
- MediPoint: Drug-Eluting Balloons - APAC Analysis and Market Forecasts
- Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies
- Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
- MediPoint: Drug-Eluting Balloons - US Analysis and Market Forecasts
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013
- MediPoint: Drug-Eluting Balloons - South American Analysis and Market Forecasts
- Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth